期刊
ACTA HAEMATOLOGICA
卷 144, 期 3, 页码 308-313出版社
KARGER
DOI: 10.1159/000509922
关键词
Inherited thrombocytopenia; Eltrombopag; FLI1; RUNX1; ETV6
类别
Inherited thrombocytopenias are a group of hereditary disorders with reduced platelet count and platelet dysfunction caused by gene mutations. High-dose oral non-peptide thrombopoietin receptor agonist treatment can effectively alleviate symptoms in patients with severe syndromic inherited thrombocytopenia.
Inherited thrombocytopenias correspond to a group of hereditary disorders characterized by a reduced platelet count, platelet dysfunction, and a family history of thrombocytopenia. It is commonly associated with mucocutaneous bleeding. Thrombocytopenia results from mutations in genes involved in megakaryocyte differentiation, platelet formation, and clearance. Here we report on a patient presenting with severe syndromic inherited thrombocytopenia manifesting as spontaneous mucocutaneous bleeds, requiring frequent platelet transfusions. Thrombocytopenia was explained by the presence of 4 mutations in 3 hematopoietic transcription factor genes: FLI1, RUNX1, and ETV6. The patient was successfully treated with high-dose eltrombopag at 150 mg/day, an orally available non-peptide thrombopoietin receptor agonist. Since the start of treatment 23 months ago, the manifestations of bleeding have resolved, and no platelet transfusions or corticosteroids have been required. The patient has no clinical or laboratory evidence of myeloid malignancy so far.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据